HER2 as a marker for guiding the choice of chemotherapy in breast cancer patients
Patients diagnosed with local or locally advanced breast cancer are treated by a combination of surgery, radiation therapy and drug therapy (chemotherapy, biological and hormonal therapy). Recently, efforts have been made to customize drug treatment according to subgroups that will derive maximum benefit from a specific treatment. This goal is accomplished by the assessment of standard variables, among them specific receptors of the tumor and customization of treatment accordingly. For example, treatment with Herceptin is known to be beneficial only in patients with HER2 positive tumors. It has recently been suggested that this group also derives greater benefit from treatment with anthracyclines.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:149 |
|---|---|
| Enthalten in: |
Harefuah - 149(2010), 12 vom: 01. Dez., Seite 807-8, 810 |
| Sprache: |
Hebräisch |
|---|
| Beteiligte Personen: |
Zick, Aviad [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 29.09.2011 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM211457051 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM211457051 | ||
| 003 | DE-627 | ||
| 005 | 20231224013559.0 | ||
| 007 | tu | ||
| 008 | 231224s2010 xx ||||| 00| ||heb c | ||
| 028 | 5 | 2 | |a pubmed24n0705.xml |
| 035 | |a (DE-627)NLM211457051 | ||
| 035 | |a (NLM)21916107 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a heb | ||
| 100 | 1 | |a Zick, Aviad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HER2 as a marker for guiding the choice of chemotherapy in breast cancer patients |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 29.09.2011 | ||
| 500 | |a Date Revised 19.11.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Patients diagnosed with local or locally advanced breast cancer are treated by a combination of surgery, radiation therapy and drug therapy (chemotherapy, biological and hormonal therapy). Recently, efforts have been made to customize drug treatment according to subgroups that will derive maximum benefit from a specific treatment. This goal is accomplished by the assessment of standard variables, among them specific receptors of the tumor and customization of treatment accordingly. For example, treatment with Herceptin is known to be beneficial only in patients with HER2 positive tumors. It has recently been suggested that this group also derives greater benefit from treatment with anthracyclines | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Anthracyclines |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a ERBB2 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 700 | 1 | |a Appelbaum, Limor |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Harefuah |d 1946 |g 149(2010), 12 vom: 01. Dez., Seite 807-8, 810 |w (DE-627)NLM000070491 |x 0017-7768 |7 nnns |
| 773 | 1 | 8 | |g volume:149 |g year:2010 |g number:12 |g day:01 |g month:12 |g pages:807-8, 810 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 149 |j 2010 |e 12 |b 01 |c 12 |h 807-8, 810 | ||